Lead, Innovate, Transform
AEON Biopharma is a biopharmaceutical company focused on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. ABP-450 has the same 900 kDa complex size as the market leader, and, if approved, will be the only therapeutic botulinum toxin with significantly similar physiochemical properties as the market leader.
We are dedicated to enhancing patient lives by leading in new ways to use botulinum toxins while improving existing botulinum toxin therapy.
Our core values guide our company and
every decision we make.
We recognize the great promise and value that comes from fresh and creative thinking. We aim to transform the therapeutic use of botulinum toxins with the introduction of ABP-450.
At AEON, we believe that great achievements are realized when passionate people work together towards a compelling vision.
We understand how difficult it is to suffer from the pain and decreased functionality arising from a medical disorder. At AEON, patients are at the heart of everything we do.
We understand that to innovate we must look forward constantly, adapt effectively and implement quickly.
We believe in building an inspiring vision, setting the direction, and blazing new trails.
Interested in AEON Biopharma?
Learn more about us and our breakthrough botulinum toxin therapy treatment.